09:39:18 EDT Sun 23 Jun 2024
Enter Symbol
or Name
USA
CA



Cybin Inc
Symbol CYBN
Shares Issued 410,855,285
Close 2024-02-07 C$ 0.395
Market Cap C$ 162,287,838
Recent Sedar Documents

Cybin receives two patents in Japan for DMT program

2024-02-07 11:55 ET - News Release

Mr. Doug Drysdale reports

CYBIN ANNOUNCES GRANT OF TWO ADDITIONAL PATENTS IN JAPAN IN SUPPORT OF ITS DMT PROGRAM

The Japan Patent (JP) Office has granted JP patents 2023-500532 and 2023-533436 to Cybin Inc.

The patents, which are expected to provide exclusivity until at least 2040 and 2041, respectively, include protection for a synthesis method for the preparation of DMT (N,N-dimethyltryptamine) and dDMT (deuterated DMT) and injectable formulations within the company's proprietary DMT program in clinical development for the treatment of generalized anxiety disorder (GAD).

"The issuance of these patents by the Japan Patent Office serves to further strengthen and broaden our intellectual property portfolio in key global markets as we advance our clinical programs," said Doug Drysdale, chief executive officer of Cybin. "Japan is a major pharmaceutical market, and the patents serve as further validation of our research and development efforts to bring improved treatment options globally for a multitude of mental health disorders. Vigorously protecting our proprietary work is a strategic priority for us, and we are delighted that these patents add to our existing U.S. and European patent portfolio and provide protection for our proprietary DMT program in another important region."

In January, the company announced that the U.S. Food and Drug Administration cleared its investigational new drug application for CYB004, its proprietary dDMT molecule in development for the treatment of GAD. This clearance allows the company to proceed with its plans to initiate a phase 2a study of CYB004 in Q1 2024. The phase 2a study will be a randomized, double-blind, active-controlled trial to assess the preliminary clinical efficacy, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of CYB004 in participants with GAD.

In January, the company also announced positive safety, pharmacokinetic and pharmacodynamic data from its phase 1 studies of CYB004 (intravenous) and SPL028 (intravenous and intramuscular) in healthy volunteers. CYB004 and SPL028 are proprietary deuterated DMT molecules within the company's DMT program in development for the treatment of GAD.

About Cybin Inc.

Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions.

Cybin's goal of revolutionizing mental health care is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The company is currently developing CYB003, a proprietary deuterated psilocybin analogue for the treatment of major depressive disorder, and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder, and has a research pipeline of investigational psychedelic-based compounds.

Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.